CARLSBAD, Calif., April 22 /PRNewswire-FirstCall/ -- Genoptix, Inc. , a provider of personalized diagnostic services, announced today that it expects to report its financial results for the first quarter after closing of the NASDAQ Global Market on Thursday, May 8, 2008.
A conference call hosted by President and CEO Tina Nova Bennett, Ph.D. and other members of senior management will take place on the same day at 2:00pm PDT (5:00pm EDT) and will be webcast live on the Genoptix website.
To access the live conference call via phone, dial 866-277-1181 in the U.S. or Canada and 617-597-5358 for international callers. Please specify to the operator that you would like to join the “Genoptix First Quarter 2008 Earnings Conference Call.” The participant code for the call is 26333972. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, May 15, 2008. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 99500372.
The conference call will be webcast live on the Internet and is accessible through the investor relations section of the Genoptix website at http://www.genoptix.com, or by accessing the external website, http://www.fulldisclosure.com. To participate in the webcast, please connect to the Genoptix website several minutes prior to the start time to register, download and install any necessary software that may be required. An online replay is planned to follow shortly after and will be available until Monday, June 9, 2008.
Due to the timing of the Company’s quarterly earnings release, the lock-up agreements between the underwriters and certain Genoptix stockholders, which was entered into in conjunction with its initial public offering (IPO), will automatically be extended an additional 18 days from the date the Company reports results for the first quarter. As a result of this automatic extension, no shares subject to the IPO lock-up agreement may be traded prior to Tuesday, May 27, 2008, the first trading day after its expiration, unless such lock-up restriction is waived in writing by the underwriters for our IPO.
About Genoptix, Inc.
Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community- based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.
Any statements in this press release or that may be made on the Genoptix conference call about expectations, beliefs, plans, objectives, assumptions or future events, including the extension and expiration of the IPO lock-up agreement, or future performance are not historical facts and are forward- looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties that Genoptix faces, please refer to the risk factors section of the annual report on Form 10-K for the full-year ended December 31, 2007 filed with the United States Securities and Exchange Commission on February 12, 2008, as well as other subsequent filings with the Securities and Exchange Commission. Genoptix assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
CONTACT: Marcy Graham, Sr. Director, Investor Relations of Genoptix, Inc.,
+1-760-930-7150, investorrelations@genoptix.com; or Joleen Schultz,
Principal of Mentus, +1-858-455-5500, ext. 215, jschultz@mentus.com, for
Genoptix, Inc.
Web site: http://www.genoptix.com/
